443 related articles for article (PubMed ID: 21447798)
41. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
42. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
43. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
[TBL] [Abstract][Full Text] [Related]
44. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
45. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Yoon J; Koo KH; Choi KY
Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
[TBL] [Abstract][Full Text] [Related]
46. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.
Falck Miniotis M; Arunan V; Eykyn TR; Marais R; Workman P; Leach MO; Beloueche-Babari M
Cancer Res; 2013 Jul; 73(13):4039-49. PubMed ID: 23639941
[TBL] [Abstract][Full Text] [Related]
47. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
Clarke PA; Roe T; Swabey K; Hobbs SM; McAndrew C; Tomlin K; Westwood I; Burke R; van Montfort R; Workman P
Oncogene; 2019 Jun; 38(25):5076-5090. PubMed ID: 30905967
[TBL] [Abstract][Full Text] [Related]
48. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
[TBL] [Abstract][Full Text] [Related]
49. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract][Full Text] [Related]
51. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
52. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
Bekaii-Saab T; Phelps MA; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA
J Clin Oncol; 2011 Jun; 29(17):2357-63. PubMed ID: 21519026
[TBL] [Abstract][Full Text] [Related]
53. AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
Flemington V; Davies EJ; Robinson D; Sandin LC; Delpuech O; Zhang P; Hanson L; Farrington P; Bell S; Falenta K; Gibbons FD; Lindsay N; Smith A; Wilson J; Roberts K; Tonge M; Hopcroft P; Willis SE; Roudier MP; Rooney C; Coker EA; Jaaks P; Garnett MJ; Fawell SE; Jones CD; Ward RA; Simpson I; Cosulich SC; Pease JE; Smith PD
Mol Cancer Ther; 2021 Feb; 20(2):238-249. PubMed ID: 33273059
[TBL] [Abstract][Full Text] [Related]
54. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
Sale MJ; Cook SJ
Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
[TBL] [Abstract][Full Text] [Related]
55. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
[TBL] [Abstract][Full Text] [Related]
56. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
57. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
[TBL] [Abstract][Full Text] [Related]
58. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
Morris VK; Lucas FAS; Overman MJ; Eng C; Morelli MP; Jiang ZQ; Luthra R; Meric-Bernstam F; Maru D; Scheet P; Kopetz S; Vilar E
Ann Oncol; 2014 Oct; 25(10):2008-2014. PubMed ID: 25009008
[TBL] [Abstract][Full Text] [Related]
60. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
